How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone
Product Development
Data Byte
More than 60% of company’s revenues derived from the U.S.
Politics, Policy & Law
Madrigal prepares to launch its MASH drug. BCMA-directed CAR Ts go before FDA’s ODAC
Deals
Plus: Merck gains access to Pearl Bio’s synthetic biology platform for up to $1B, Hansoh partners with Biotheus on bispecific ADCs, and more
Management Tracks
Plus: Everest hires Sandra Zeng as CMO and Rico Liang as chief product officer, and updates from Parexel, Dignify and GRO
BioCentury ISSN 1097-7201